Kurji and his team at Cyclica are using their computational drug discovery platform to strategize potential repurposing options for the treatment of COVID-19. The company has been in touch with leading Chinese research institutes, and this week finalized an agreement with the Institute of Materia Medica, Chinese Academy of Medical Sciences in Beijing. They are teaming up with local researchers in a socially responsible way to provide a unique attempt at a solution.